$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007481 Filed on March 14, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$446.0K	$112.0K	$377.0K
YoY Change	135.98%	-62.67%	-24.6%
Cost Of Revenue	$1.346M	$1.618M	$3.614M
YoY Change	264.77%	266.89%	517.78%
Gross Profit	-$900.0K	-$1.506M	-$3.237M
YoY Change	400.0%	968.09%	3708.24%
Gross Profit Margin	-201.79%	-1344.64%	-858.62%
Selling, General & Admin	$14.56M	$15.82M	$60.36M
YoY Change	10.07%	25.85%	76.31%
% of Gross Profit
Research & Development	$4.439M	$6.674M	$25.55M
YoY Change	-25.17%	-4.23%	28.72%
% of Gross Profit
Depreciation & Amortization	$727.0K	$726.0K	$2.457M
YoY Change	236.57%	337.35%	987.17%
% of Gross Profit
Operating Expenses	$19.00M	$23.00M	$85.91M
YoY Change	-1.47%	17.71%	58.18%
Operating Profit	-$20.40M	-$24.50M	-$90.93M
YoY Change	4.84%	24.52%	67.17%
Interest Expense	-$1.102M	$243.0K	-$2.545M
YoY Change			-251.31%
% of Operating Profit
Other Income/Expense, Net	-$1.813M	$0.00	-$12.31M
YoY Change	947.98%		610.39%
Pretax Income	-$22.21M	-$24.57M	-$103.2M
YoY Change	13.15%	24.86%	83.94%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$17.93M	-$20.53M	-$88.98M
YoY Change	6.28%	19.25%	76.74%
Net Earnings / Revenue	-4020.4%	-18332.14%	-23602.92%
Basic Earnings Per Share	-$0.18		-$1.00
Diluted Earnings Per Share	-$0.19	-$0.22	-$1.00
COMMON SHARES
Basic Shares Outstanding	98.42M shares	93.70M shares	89.08M shares
Diluted Shares Outstanding	6.473M shares		5.938M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.81M	$42.75M	$42.75M
YoY Change	-22.01%	-45.17%	-45.17%
Cash & Equivalents	$49.28M	$39.74M	$3.005M
Short-Term Investments
Other Short-Term Assets	$1.004M	$1.160M	$1.160M
YoY Change	-68.65%	-74.03%	-74.03%
Inventory		$111.0K
Prepaid Expenses
Receivables	$27.00K	$17.00K	$17.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$53.84M	$43.93M	$43.93M
YoY Change	-24.17%	-46.84%	-46.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.255M	$2.451M	$5.488M
YoY Change	-55.05%	54.64%	246.25%
Goodwill
YoY Change
Intangibles	$2.940M	$3.445M
YoY Change		69.79%
Long-Term Investments
YoY Change
Other Assets	$1.079M	$1.121M	$1.121M
YoY Change	55.25%	54.62%	54.62%
Total Long-Term Assets	$11.45M	$10.05M	$10.05M
YoY Change	-14.15%	131.71%	131.71%
TOTAL ASSETS
Total Short-Term Assets	$53.84M	$43.93M	$43.93M
Total Long-Term Assets	$11.45M	$10.05M	$10.05M
Total Assets	$65.29M	$53.98M	$53.98M
YoY Change	-22.59%	-37.94%	-37.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.258M	$2.704M	$2.704M
YoY Change	-84.72%	-18.04%	-18.04%
Accrued Expenses	$3.724M	$3.705M	$3.705M
YoY Change	6.46%	-13.01%	-13.01%
Deferred Revenue
YoY Change
Short-Term Debt	$45.56M	$34.79M	$34.79M
YoY Change	5119.24%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$50.55M	$41.20M	$41.20M
YoY Change	188.95%	445.12%	445.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.936M	$1.846M	$1.846M
YoY Change	86.72%
Total Long-Term Liabilities	$3.936M	$1.846M	$1.846M
YoY Change	86.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$50.55M	$41.20M	$41.20M
Total Long-Term Liabilities	$3.936M	$1.846M	$1.846M
Total Liabilities	$54.48M	$43.05M	$63.66M
YoY Change	41.87%	469.54%	151.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$246.2M	-$228.2M
YoY Change		64.26%
Common Stock	$101.0K	$95.00K
YoY Change		10.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$408.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$22.06M	-$9.681M	-$9.681M
YoY Change
Total Liabilities & Shareholders Equity	$65.29M	$53.98M	$53.98M
YoY Change	-22.59%	-37.94%	-37.94%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$17.93M	-$20.53M	-$88.98M
YoY Change	6.28%	19.25%	76.74%
Depreciation, Depletion And Amortization	$727.0K	$726.0K	$2.457M
YoY Change	236.57%	337.35%	987.17%
Cash From Operating Activities	-$16.29M	-$16.82M	-$70.99M
YoY Change	32.81%	0.27%	74.88%
INVESTING ACTIVITIES
Capital Expenditures	$26.00K	$298.0K	$1.540M
YoY Change	-104.53%	-123.34%	-204.83%
Acquisitions			$3.200M
YoY Change			42.41%
Other Investing Activities	$1.000M	$0.00	-$3.200M
YoY Change		-100.0%	42.41%
Cash From Investing Activities	$974.0K	-$298.0K	-$4.740M
YoY Change	-269.69%	-91.18%	27.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$24.85M	80.00K	$38.21M
YoY Change	7763.61%	-99.87%	-63.37%
NET CHANGE
Cash From Operating Activities	-$16.29M	-16.82M	-$70.99M
Cash From Investing Activities	$974.0K	-298.0K	-$4.740M
Cash From Financing Activities	$24.85M	80.00K	$38.21M
Net Change In Cash	$9.536M	-17.04M	-$37.51M
YoY Change	-176.16%	-142.69%	-162.52%
FREE CASH FLOW
Cash From Operating Activities	-$16.29M	-$16.82M	-$70.99M
Capital Expenditures	$26.00K	$298.0K	$1.540M
Free Cash Flow	-$16.31M	-$17.12M	-$72.53M
YoY Change	39.56%	10.46%	85.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Secured Debt Current SecuredDebtCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2021	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
CY2022	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue		usd
CY2022	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2021	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess		usd
CY2021	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment		usd
CY2021	PAVM	Loss Upon Issuance Senior Secured Convertible Note LossUponIssuanceSeniorSecuredConvertibleNote		usd
CY2022	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness		usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	PAVM	Repayments Of Convertible Debt Non Installment Payments RepaymentsOfConvertibleDebtNonInstallmentPayments		usd
CY2021	PAVM	Proceeds From Issuance Of Common Stock At The Market Facility ProceedsFromIssuanceOfCommonStockAtTheMarketFacility		usd
CY2021	PAVM	Proceeds Majorityowned Subsidiary Common Stock Committed Equity Facility ProceedsMajorityownedSubsidiaryCommonStockCommittedEquityFacility		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	PAVM	Proceeds From Warrant Exercises Two ProceedsFromWarrantExercisesTwo		usd
CY2021	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan		usd
CY2021	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary		usd
CY2021	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation		usd
CY2021Q4	PAVM	Veris Box Supplies VerisBoxSupplies		usd
CY2022Q4	PAVM	Prepaid Carp X Device PrepaidCarpXDevice		usd
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent		pure
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Investement Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestInvestementValue		usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value One AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueOne		usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Two AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueTwo		usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue		usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Three AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueThree		usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues		usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2021Q4	PAVM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2021Q4	PAVM	Deferred Tax Assets Tax Depreciation And Amortization DeferredTaxAssetsTaxDepreciationAndAmortization		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37685
CY2022	dei	Entity Registrant Name EntityRegistrantName	PAVMED INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1214177
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Madison Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	25th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2022	dei	City Area Code CityAreaCode	(212)
CY2022	dei	Local Phone Number LocalPhoneNumber	949-4319
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	70500000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98419795	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39744000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77258000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	200000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4165000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5179000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43926000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	82637000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2451000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1585000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3445000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2029000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1121000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	725000	usd
CY2022Q4	us-gaap	Assets Assets	53980000	usd
CY2021Q4	us-gaap	Assets Assets	86976000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2704000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3299000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3705000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4259000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	33650000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41200000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7558000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	43046000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7558000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2695000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	2419000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94510537	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94510537	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86367845	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86367845	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	95000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	86000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	216106000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198071000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228169000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138910000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	408000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9681000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	61666000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	17752000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53980000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86976000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	377000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3614000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	585000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19318000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8895000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41041000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25420000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1784000	usd
CY2021	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue	7804000	usd
CY2021	PAVM	Issue Common Stock Exercise Series W Warrants Value IssueCommonStockExerciseSeriesWWarrantsValue	20000	usd
CY2021	PAVM	Issue Common Stock Upon Partial Conversions Of Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfSeniorSecuredConvertibleNote	1723000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	146000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25547000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19847000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	91304000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	54893000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-90927000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-54393000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	1272000	usd
CY2022	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1273000	usd
CY2021	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-1682000	usd
CY2022	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	4332000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-5434000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3715000	usd
CY2021	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness	300000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12311000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1733000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103238000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56126000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-56126000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5779000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-88983000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-50347000	usd
CY2022	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	281000	usd
CY2021	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	283000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89264000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50630000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-1.00
CY2021	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.65
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89076078	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77515767	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2022	PAVM	Stock Issued During Period Value Atm Facility StockIssuedDuringPeriodValueATMFacility	79000	usd
CY2022	PAVM	Issue Common Stock Upon Partial Conversions Of Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfSeniorSecuredConvertibleNote	11807000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	302000	usd
CY2022	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	695000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	358000	usd
CY2022	PAVM	Purchase Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	109000	usd
CY2022	PAVM	Issuance Majorityowned Subsidiary Common Stock Committed Equity Facility Net Of Deferred Financing Charges IssuanceMajorityownedSubsidiaryCommonStockCommittedEquityFacilityNetOfDeferredFinancingCharges	1767000	usd
CY2022	PAVM	Issuance Majorityowned Subsidiary Common Stock Settlement Apardx Installment Payment IssuanceMajorityownedSubsidiaryCommonStockSettlementApardxInstallmentPayment	653000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	5666000	usd
CY2022	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	13866000	usd
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-548000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-473000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-473000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	53704000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	979000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	436000	usd
CY2021	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions	56336000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	5410000	usd
CY2021	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	9599000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	6000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-56126000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-56126000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2457000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	226000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19532000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15009000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	133000	usd
CY2022	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	653000	usd
CY2022	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1273000	usd
CY2021	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-1682000	usd
CY2022	PAVM	Loss Upon Issuance Senior Secured Convertible Note LossUponIssuanceSeniorSecuredConvertibleNote	3523000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-5434000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3715000	usd
CY2021	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness	300000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	97000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-183000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	200000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-397000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3458000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-742000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	174000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-554000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1918000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70985000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40591000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1540000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1469000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3200000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2247000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4740000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3716000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	62000000	usd
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	5665000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55016000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1312000	usd
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	35227000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	14816000	usd
CY2021	PAVM	Repayments Of Convertible Debt Non Installment Payments RepaymentsOfConvertibleDebtNonInstallmentPayments	154000	usd
CY2022	PAVM	Proceeds From Issuance Of Common Stock At The Market Facility ProceedsFromIssuanceOfCommonStockAtTheMarketFacility	79000	usd
CY2022	PAVM	Proceeds Majorityowned Subsidiary Common Stock Committed Equity Facility ProceedsMajorityownedSubsidiaryCommonStockCommittedEquityFacility	1807000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7804000	usd
CY2021	PAVM	Proceeds From Warrant Exercises Two ProceedsFromWarrantExercisesTwo	20000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	302000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	980000	usd
CY2022	PAVM	Proceeds From Issue Of Common Stock Employee Stock Purchase Plan ProceedsFromIssueOfCommonStockEmployeeStockPurchasePlan	358000	usd
CY2021	PAVM	Proceeds From Issue Of Common Stock Employee Stock Purchase Plan ProceedsFromIssueOfCommonStockEmployeeStockPurchasePlan	436000	usd
CY2022	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	109000	usd
CY2022	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary	695000	usd
CY2022	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation	366000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38211000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104309000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37514000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60002000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	77258000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17256000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	77258000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zYFR2aT0yXyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_82D_zDHt0SIt8rC5">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed Inc and Subsidiaries, referred to herein as “PAVmed” or the “Company,” is comprised of PAVmed Inc. and its wholly-owned subsidiary and its majority-owned subsidiaries, inclusive of Lucid Diagnostics Inc. (“Lucid Diagnostics” or “LUCID”) and Veris Health Inc. (“Veris Health” or “VERIS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed is a highly differentiated, multi-product, commercial-stage medical technology company organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current central focus is predominantly on commercial expansion and execution including the acceleration of EsoGuard and Veris Cancer Care Platform commercialization. As resources permit, we will continue to explore internal and external innovations that fulfill our project selection criteria without limiting ourselves to any target specialty or condition. More broadly, we strive to maintain balance within our pipeline with shorter-term, lower-risk projects with the prospect for rapid commercialization and revenue generation supporting development of longer-term projects. At the same time, we are continuously re-assessing each project’s long-term commercial potential relative to other projects in our pipeline, accelerating or decelerating the project and reallocating resources accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in one segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices and Digital Health. Above in <i>Part I, Item 1 - Business</i> is a summary of each of our key products within these sectors, including in particular EsoGuard and the Veris Cancer Care Platform, currently our two leading products. We are also pursuing a number of research and development project and product opportunities across these three lines of business, which have either been developed internally or have been presented to us by clinician innovators and academic medical institutions for consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zKrxPjcAfSV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zXA14c2RMb94">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets, inclusive of acquired intangible assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these consolidated financial statements include those related to the estimated fair value of stock-based equity awards, intangible assets, financial instruments recognized as liabilities, debt obligations, and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 — Summary of Significant Accounting Policies</b> - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3614000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	585000	usd
CY2022	PAVM	License Fee LicenseFee	273000	usd
CY2021Q3	PAVM	License Agreement Remaining Balance LicenseAgreementRemainingBalance	223000	usd
CY2022	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likelihood
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zzNBA7No0HRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zUTrOhfM00U5">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the consolidated financial statements and accompanying notes to the consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	377000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	500000	usd
CY2022	PAVM	Monthly Fees MonthlyFees	100000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	500000	usd
CY2021Q3	PAVM	Amendment Fee AmendmentFee	10000	usd
CY2022	PAVM	Non Refundable Commercialization Milestone Payment Amount NonRefundableCommercializationMilestonePaymentAmount	100000	usd
CY2022	PAVM	Future Royalties Fees Based On Future Net Sales FutureRoyaltiesFeesBasedOnFutureNetSales	150000	usd
CY2022	us-gaap	Deferred Revenue Period Increase Decrease DeferredRevenuePeriodIncreaseDecrease	300000	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	100000000.0	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	600000	usd
CY2022	PAVM	Royalty Fee Payment Liability Percentage RoyaltyFeePaymentLiabilityPercentage	0.050	pure
CY2022	us-gaap	Royalty Expense RoyaltyExpense	23000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	25000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1649000	usd
CY2021	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1338000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3200000	usd
CY2022Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	599000	usd
CY2021Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	808000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	300000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1856000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	3005000	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	1989000	usd
CY2022Q4	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	59000	usd
CY2021Q4	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	434000	usd
CY2022Q4	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	52000	usd
CY2021Q4	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	59000	usd
CY2022Q4	PAVM	Veris Box Supplies VerisBoxSupplies	150000	usd
CY2021Q4	PAVM	Prepaid Carp X Device PrepaidCarpXDevice	33000	usd
CY2022Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	4165000	usd
CY2021Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	5179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3259000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1723000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	808000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	138000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2451000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1585000	usd
CY2022	us-gaap	Depreciation Depreciation	673000	usd
CY2021	us-gaap	Depreciation Depreciation	80000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1174000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	191000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	191000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	52000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1417000	usd
CY2021	us-gaap	Lease Cost LeaseCost	191000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1327000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1275000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	323000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	272000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	132000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3329000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	342000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2987000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1078000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3949000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M2D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2987000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	3200000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1930000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	146000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3445000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2029000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1784000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	146000	usd
CY2022	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1273000	usd
CY2022	PAVM	Fair Value Of Non Cash Expense FairValueOfNonCashExpense	3550000	usd
CY2022	PAVM	Decreases In Fair Value Remeasurements DecreasesInFairValueRemeasurements	2277000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2021000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	688000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	421000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	315000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3445000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1947000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3151000	usd
CY2022Q4	PAVM	Amended License Agreement Royalty Fee AmendedLicenseAgreementRoyaltyFee	10000	usd
CY2021Q4	PAVM	Amended License Agreement Royalty Fee AmendedLicenseAgreementRoyaltyFee	25000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1748000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1083000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3705000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4259000	usd
CY2020Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	450000	usd
CY2020Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	450000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	33650000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	27500000	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	11250000	usd
CY2021	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-1682000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32747000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	33650000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3715000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19532000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15009000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6193000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1719000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	428000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	311000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	897000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	15000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	16000	usd
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	3.00
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	PAVM	Increase In Common Stock Shares Authorized IncreaseInCommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022	PAVM	Stock Issued During Period Shares Atm Facility StockIssuedDuringPeriodSharesATMFacility	106225	shares
CY2022	PAVM	Stock Issued During Period Value Atm Facility StockIssuedDuringPeriodValueATMFacility	79000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	17752000	usd
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-2369000	usd
CY2021	PAVM	Adjustments To Additional Paid In Capital Minority Interest Investement Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestInvestementValue	6000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5779000	usd
CY2022	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	28000	usd
CY2021	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	16760000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value One AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueOne	1767000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Two AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueTwo	653000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue	695000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Three AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueThree	109000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13859000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9134000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	7000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	17752000	usd
CY2022Q4	PAVM	Deferred Tax Assets Tax Depreciation And Amortization DeferredTaxAssetsTaxDepreciationAndAmortization	221000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58354000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44421000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	850000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	22000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	36000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	850000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-24265000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9528000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11124000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-9409000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-13141000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-18937000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13141000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18937000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.132	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.013	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.152	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.127	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.337	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37032000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35989000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	922000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11105000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7091000	usd
CY2022Q4	PAVM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	836000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	58000	usd
CY2022Q4	PAVM	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	57504000	usd
CY2021Q4	PAVM	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	44363000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57504000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44363000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13141000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18937000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	158400000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	13800000	usd
CY2022	PAVM	Operating Loss Carry Forward Expiration Description OperatingLossCarryForwardExpirationDescription	statutory expiration dates commencing in 2037
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	144600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	157800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1700000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-56126000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5779000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-88983000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-50347000	usd
CY2022	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-281000	usd
CY2021	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-283000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89264000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50630000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89076078	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77515767	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-1.00
CY2021	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.65
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25686864	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23816111	shares

Files In Submission

Name	View Source	Status
pavm-20221231_def.xml	Edgar Link	unprocessable
0001493152-23-007481-index-headers.html	Edgar Link	pending
0001493152-23-007481-index.html	Edgar Link	pending
0001493152-23-007481.txt	Edgar Link	pending
0001493152-23-007481-xbrl.zip	Edgar Link	pending
ex10-12.htm	Edgar Link	pending
ex10-13.htm	Edgar Link	pending
ex10-14_2.htm	Edgar Link	pending
ex10-9.htm	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
pavm-20221231_cal.xml	Edgar Link	unprocessable
pavm-20221231_lab.xml	Edgar Link	unprocessable
pavm-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2023 Q1 Form 10-K Financial Statement

#000149315223007481 Filed on March 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2023 Q1 Form 10-K Financial Statement

#000149315223007481 Filed on March 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm